Oncology
Advanced Renal Cancer
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Advanced Renal Cancer is an early-stage landscape with 0 programs across 2 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chongqing Precision Biotech Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Unknown status2 · 33%
Active, not recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Active, not recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolledData sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)